Colon cancer is known to generate a variety of RAGE ligands, including HMGB1 and S100 molecules, suggesting that while oncogenic K-Ras itself may be “non-pharmacological,” it may be possible to inhibit or modulate its role in cancer by blocking the critical feed-forward mechanism in which RAGE plays an important role. Here, KRAS is linked to cancer.